Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Antiviral Drugs Advisory Committee
Hilton
DRAFT
AGENDA
The Antiviral Drugs Advisory Committee will discuss new
drug application (NDA) 021-814, proposed tradename Aptivus (Tipranavir) 250
milligrams (mg) capsules, Boehringer Ingelheim Pharmaceuticals, Inc., indicated for the
treatment of patients with HIV.
Introduction
of Committee
Conflict of
Interest Statement Anuja Patel, M.P.H.
Executive
Secretary, FDA
Overview of Issues
Sponsor Presentations
FDA Presentations
Lunch
Open Public Hearing
Discussion and Questions
to the Committee